Literature DB >> 27525442

Calpain-6 confers atherogenicity to macrophages by dysregulating pre-mRNA splicing.

Takuro Miyazaki, Kazuo Tonami, Shoji Hata, Toshihiro Aiuchi, Koji Ohnishi, Xiao-Feng Lei, Joo-Ri Kim-Kaneyama, Motohiro Takeya, Hiroyuki Itabe, Hiroyuki Sorimachi, Hiroki Kurihara, Akira Miyazaki.   

Abstract

Macrophages contribute to the development of atherosclerosis through pinocytotic deposition of native LDL-derived cholesterol in macrophages in the vascular wall. Inhibiting macrophage-mediated lipid deposition may have protective effects in atheroprone vasculature, and identifying mechanisms that potentiate this process may inform potential therapeutic interventions for atherosclerosis. Here, we report that dysregulation of exon junction complex-driven (EJC-driven) mRNA splicing confers hyperpinocytosis to macrophages during atherogenesis. Mechanistically, we determined that inflammatory cytokines induce an unconventional nonproteolytic calpain, calpain-6 (CAPN6), which associates with the essential EJC-loading factor CWC22 in the cytoplasm. This association disturbs the nuclear localization of CWC22, thereby suppressing the splicing of target genes, including those related to Rac1 signaling. CAPN6 deficiency in LDL receptor-deficient mice restored CWC22/EJC/Rac1 signaling, reduced pinocytotic deposition of native LDL in macrophages, and attenuated macrophage recruitment into the lesions, generating an atheroprotective phenotype in the aorta. In macrophages, the induction of CAPN6 in the atheroma interior limited macrophage movements, resulting in a decline in cell clearance from the lesions. Consistent with this finding, we observed that myeloid CAPN6 contributed to atherogenesis in a murine model of bone marrow transplantation. Furthermore, macrophages from advanced human atheromas exhibited increased CAPN6 induction and impaired CWC22 nuclear localization. Together, these results indicate that CAPN6 promotes atherogenicity in inflamed macrophages by disturbing CWC22/EJC systems.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27525442      PMCID: PMC5004959          DOI: 10.1172/JCI85880

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

Review 1.  Rho proteins: linking signaling with membrane trafficking.

Authors:  A J Ridley
Journal:  Traffic       Date:  2001-05       Impact factor: 6.215

2.  Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Venkateswaran Subramanian; Haruhito A Uchida; Talha Ijaz; Jessica J Moorleghen; Deborah A Howatt; Anju Balakrishnan
Journal:  J Cardiovasc Pharmacol       Date:  2012-01       Impact factor: 3.105

3.  m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis.

Authors:  Takuro Miyazaki; Yoshitaka Taketomi; Masafumi Takimoto; Xiao-Feng Lei; Shigeko Arita; Joo-ri Kim-Kaneyama; Satoru Arata; Hisayuki Ohata; Hidekazu Ota; Makoto Murakami; Akira Miyazaki
Journal:  Circulation       Date:  2011-11-07       Impact factor: 29.690

4.  The small GTP-binding protein rac regulates growth factor-induced membrane ruffling.

Authors:  A J Ridley; H F Paterson; C L Johnston; D Diekmann; A Hall
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

5.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

Authors:  Frank Tacke; David Alvarez; Theodore J Kaplan; Claudia Jakubzick; Rainer Spanbroek; Jaime Llodra; Alexandre Garin; Jianhua Liu; Matthias Mack; Nico van Rooijen; Sergio A Lira; Andreas J Habenicht; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

6.  NADPH oxidase deficiency exacerbates angiotensin II-induced abdominal aortic aneurysms in mice.

Authors:  Yasuyoshi Kigawa; Takuro Miyazaki; Xiao-Feng Lei; Tomoya Nakamachi; Tatsunori Oguchi; Joo-ri Kim-Kaneyama; Matsuo Taniyama; Shohko Tsunawaki; Seiji Shioda; Akira Miyazaki
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-04       Impact factor: 8.311

7.  Calpain 8/nCL-2 and calpain 9/nCL-4 constitute an active protease complex, G-calpain, involved in gastric mucosal defense.

Authors:  Shoji Hata; Manabu Abe; Hidenori Suzuki; Fujiko Kitamura; Noriko Toyama-Sorimachi; Keiko Abe; Kenji Sakimura; Hiroyuki Sorimachi
Journal:  PLoS Genet       Date:  2010-07-29       Impact factor: 5.917

8.  Fluorescent pegylated nanoparticles demonstrate fluid-phase pinocytosis by macrophages in mouse atherosclerotic lesions.

Authors:  Chiara Buono; Joshua J Anzinger; Marcelo Amar; Howard S Kruth
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

9.  The role of calpain-myosin 9-Rab7b pathway in mediating the expression of Toll-like receptor 4 in platelets: a novel mechanism involved in α-granules trafficking.

Authors:  Jui-Chi Tsai; Yi-Wen Lin; Chun-Yao Huang; Chih-Yuan Lin; Yi-Ting Tsai; Chun-Min Shih; Chung-Yi Lee; Yung-Hsiang Chen; Chi-Yuan Li; Nen-Chung Chang; Feng-Yen Lin; Chien-Sung Tsai
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  Dissecting the roles of Rac1 activation and deactivation in macropinocytosis using microscopic photo-manipulation.

Authors:  Makoto Fujii; Katsuhisa Kawai; Youhei Egami; Nobukazu Araki
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more
  13 in total

Review 1.  Emerging roles of calpain proteolytic systems in macrophage cholesterol handling.

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  Cell Mol Life Sci       Date:  2017-04-21       Impact factor: 9.261

2.  Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence.

Authors:  Caroline Andrique; Laetitia Morardet; Laetitia K Linares; Madi Y Cissé; Candice Merle; Frédéric Chibon; Sylvain Provot; Eric Haÿ; Hang-Korng Ea; Martine Cohen-Solal; Dominique Modrowski
Journal:  JCI Insight       Date:  2018-09-06

Review 3.  Dysregulation of Calpain Proteolytic Systems Underlies Degenerative Vascular Disorders.

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  J Atheroscler Thromb       Date:  2017-08-17       Impact factor: 4.928

Review 4.  Defective Protein Catabolism in Atherosclerotic Vascular Inflammation.

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  Front Cardiovasc Med       Date:  2017-12-07

5.  Deficiency of calpain-6 inhibits primary ciliogenesis.

Authors:  Bo Hye Kim; Do Yeon Kim; Sumin Oh; Je Yeong Ko; Gyuyeong Rah; Kyung Hyun Yoo; Jong Hoon Park
Journal:  BMB Rep       Date:  2019-10       Impact factor: 4.778

6.  Calpain-mediated proteolytic production of free amino acids in vascular endothelial cells augments obesity-induced hepatic steatosis.

Authors:  Risako Akasu; Takuro Miyazaki; Mohamed Z Elhussiny; Yuki Sugiura; Yuki Tomitsuka; Shogo Haraguchi; Kinya Otsu; Vishwajit S Chowdhury; Akira Miyazaki
Journal:  J Biol Chem       Date:  2022-04-18       Impact factor: 5.486

Review 7.  Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg?

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  Front Cardiovasc Med       Date:  2021-06-23

Review 8.  Calpain proteolytic systems counteract endothelial cell adaptation to inflammatory environments.

Authors:  Takuro Miyazaki; Risako Akasu; Akira Miyazaki
Journal:  Inflamm Regen       Date:  2020-04-02

9.  Electrical stimulation inhibits Val-boroPro-induced pyroptosis in THP-1 macrophages via sirtuin3 activation to promote autophagy and inhibit ROS generation.

Authors:  Lin Cong; Ziyu Gao; Yinghong Zheng; Ting Ye; Zitong Wang; Pengyu Wang; Manman Li; Bowen Dong; Wei Yang; Quanfeng Li; Shupei Qiao; Cao Wang; Yijun Shen; Hong Li; Weiming Tian; Liming Yang
Journal:  Aging (Albany NY)       Date:  2020-04-14       Impact factor: 5.682

Review 10.  CAPN6 in disease: An emerging therapeutic target (Review).

Authors:  Lin Chen; Dongqiong Xiao; Fajuan Tang; Hu Gao; Xihong Li
Journal:  Int J Mol Med       Date:  2020-09-21       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.